{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:27:26Z","timestamp":1790749646318,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["T32 AI007044"],"award-info":[{"award-number":["T32 AI007044"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.cmi.2017.07.028","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T17:00:28Z","timestamp":1501779628000},"page":"429.e1-429.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen"],"prefix":"10.1016","volume":"24","author":[{"given":"B.J.","family":"Werth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Waalkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Salipante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Rakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Butler-Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.cmi.2017.07.028_bib1","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/jac\/dki005","article-title":"Origin, structure, and activity in\u00a0vitro and in\u00a0vivo of dalbavancin","volume":"55","author":"Malabarba","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.cmi.2017.07.028_bib2","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1128\/AAC.01453-08","article-title":"Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates","volume":"53","author":"Biedenbach","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2017.07.028_bib3","series-title":"Dalvance\u2122 Package Insert","year":"2016"},{"issue":"7","key":"10.1016\/j.cmi.2017.07.028_bib4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.cmi.2017.07.028_bib5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A\u00a0randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.cmi.2017.07.028_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.diagmicrobio.2015.01.017","article-title":"Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin","volume":"82","author":"Jones","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2017.07.028_bib7","series-title":"M07\u2013A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard- tenth edition","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"issue":"3\u20135","key":"10.1016\/j.cmi.2017.07.028_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drup.2013.10.002","article-title":"Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the \u201cseesaw effect\u201d: taking advantage of the back door left open?","volume":"16","author":"Ortwine","year":"2013","journal-title":"Drug Resist Updat"},{"issue":"4","key":"10.1016\/j.cmi.2017.07.028_bib9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/47.4.399","article-title":"A\u00a0modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital","volume":"47","author":"Wootton","year":"2001","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.cmi.2017.07.028_bib10","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1128\/JCM.37.11.3556-3563.1999","article-title":"Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains","volume":"37","author":"Shopsin","year":"1999","journal-title":"J\u00a0Clin Microbiol"},{"issue":"12","key":"10.1016\/j.cmi.2017.07.028_bib11","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1128\/JCM.41.12.5442-5448.2003","article-title":"Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management","volume":"41","author":"Harmsen","year":"2003","journal-title":"J\u00a0Clin Microbiol"},{"issue":"1","key":"10.1016\/j.cmi.2017.07.028_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/sur.2009.015","article-title":"Disseminated community-acquired USA300 methicillin-resistant Staphylococcus aureus pyomyositis and septic pulmonary emboli in an immunocompetent adult","volume":"11","author":"Woodward","year":"2010","journal-title":"Surg Infect (Larchmt)"},{"issue":"4","key":"10.1016\/j.cmi.2017.07.028_bib13","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1128\/JCM.41.4.1801-1804.2003","article-title":"New method for typing Staphylococcus aureus strains: multiple-locus variable-number tandem repeat analysis of polymorphism and genetic relationships of clinical isolates","volume":"41","author":"Sabat","year":"2003","journal-title":"J\u00a0Clin Microbiol"},{"issue":"4","key":"10.1016\/j.cmi.2017.07.028_bib14","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1128\/JCM.03385-14","article-title":"Application of whole-genome sequencing for bacterial strain typing in molecular epidemiology","volume":"53","author":"Salipante","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"issue":"2","key":"10.1016\/j.cmi.2017.07.028_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A\u00a0program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (Austin)"},{"issue":"1","key":"10.1016\/j.cmi.2017.07.028_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/infdis\/jit127","article-title":"Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus","volume":"208","author":"Vidaillac","year":"2013","journal-title":"J\u00a0Infect Dis"},{"issue":"22","key":"10.1016\/j.cmi.2017.07.028_bib17","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.1073\/pnas.0609839104","article-title":"Tracking the in\u00a0vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing","volume":"104","author":"Mwangi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"148","key":"10.1016\/j.cmi.2017.07.028_bib18","doi-asserted-by":"crossref","first-page":"148ra116","DOI":"10.1126\/scitranslmed.3004129","article-title":"Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing","volume":"4","author":"Snitkin","year":"2012","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.cmi.2017.07.028_bib19","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1128\/AAC.04292-14","article-title":"Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae at a single institution: insights into endemicity from whole-genome sequencing","volume":"59","author":"Mathers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.cmi.2017.07.028_bib20","doi-asserted-by":"crossref","first-page":"e1002505","DOI":"10.1371\/journal.ppat.1002505","article-title":"Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300","volume":"8","author":"Gardete","year":"2012","journal-title":"PLoS Pathog"},{"issue":"2","key":"10.1016\/j.cmi.2017.07.028_bib21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/AAC.00395-07","article-title":"Staphylococcus aureus clinical isolate with high-level methicillin resistance with an lytH mutation caused by IS1182 insertion","volume":"52","author":"Fujimura","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.cmi.2017.07.028_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/mdr.2012.0195","article-title":"Studies on the mechanism of telavancin decreased susceptibility in a laboratory-derived mutant","volume":"19","author":"Song","year":"2013","journal-title":"Microb Drug Resist"},{"issue":"6","key":"10.1016\/j.cmi.2017.07.028_bib23","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1128\/AAC.02308-12","article-title":"Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in\u00a0vitro pharmacokinetic\/pharmacodynamic model: exploring the \u201cseesaw effect\u201d","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.cmi.2017.07.028_bib24","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1128\/JCM.41.4.1687-1693.2003","article-title":"Evolution of a vancomycin-intermediate Staphylococcus aureus strain in\u00a0vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy","volume":"41","author":"Sieradzki","year":"2003","journal-title":"J\u00a0Clin Microbiol"},{"issue":"2","key":"10.1016\/j.cmi.2017.07.028_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.diagmicrobio.2016.02.007","article-title":"Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014)","volume":"86","author":"Jones","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.cmi.2017.07.028_bib26","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.diagmicrobio.2014.05.014","article-title":"Comparative in\u00a0vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains","volume":"79","author":"Citron","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.cmi.2017.07.028_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications","volume":"23","author":"Howden","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2017.07.028_bib28","series-title":"Dalbavancin for Injection. NDA 021\u2013883","author":"Durata Therapeutics International","year":"2014"},{"issue":"5","key":"10.1016\/j.cmi.2017.07.028_bib29","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1086\/511642","article-title":"Mutant selection window hypothesis updated","volume":"44","author":"Drlica","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.cmi.2017.07.028_bib30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.cmi.2017.07.028_bib31","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1128\/AAC.00620-06","article-title":"Bactericidal activity and resistance development profiling of dalbavancin","volume":"51","author":"Goldstein","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.cmi.2017.07.028_bib32","article-title":"In\u00a0vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide","volume":"55","author":"Lopez","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.cmi.2017.07.028_bib33","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1177\/0091270008321273","article-title":"Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic","volume":"48","author":"Dowell","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.cmi.2017.07.028_bib34","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1128\/AAC.01717-15","article-title":"Impact of glycopeptide resistance in Staphylococcus aureus on the dalbavancin in\u00a0vivo pharmacodynamic target","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X17304123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X17304123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:20:43Z","timestamp":1761117643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X17304123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1198743X17304123"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2017.07.028","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2017.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}